Penetrance describes whether a defined feature appears in people who carry a particular genetic variant. Expressivity describes how that feature or condition varies between people. A condition can show both reduced penetrance and variable expressivity. Neither term, by itself, tells a person exactly what will happen to them.
This distinction helps answer two questions that often get mixed together: “Will I develop the condition?” and “If I do, what might it be like?” It also explains why relatives can have different experiences despite sharing a genetic finding. MedlinePlus explains the underlying distinction.
Penetrance vs expressivity: the practical difference
| Concept | Question it answers | What must be specified |
|---|---|---|
| Penetrance | How many people with this variant show the defined feature? | The variant, feature, population and age or observation period |
| Expressivity | Which features appear, and how do they differ? | The manifestations being compared and how they were assessed |
| Inheritance probability | What is the chance of passing on the variant? | The inheritance pattern and the parents’ actual findings |
Expressivity is a genetics term about the appearance of a phenotype. It is different from gene expression, which concerns the production of RNA or protein. Likewise, reduced penetrance does not mean that the DNA finding disappears or cannot be inherited.
A worked example: the denominator matters
Fictional teaching example. Imagine a study of 100 adults who carry the same disease-associated variant. By age 60, 60 have developed the feature the researchers defined. Within this example, the observed penetrance of that feature by age 60 is 60%. The remaining 40 have not met that definition by that age.
Now examine the 60 people with the feature. Some have mild effects, others require substantial care, and some have different organ involvement. That variation illustrates expressivity. The study has answered two different questions: the proportion meeting a definition and the range of findings among those assessed.
It would be incorrect to say that each child in these families has a 60% chance of inheriting the variant. Transmission and clinical expression are separate calculations. A clinically appropriate risk estimate also needs the correct population, age range and family context.
Age changes the meaning of “unaffected”
A relative who has no manifestations at 25 may be too young to inform the lifetime penetrance of a condition that usually appears later. An adult who has never had a relevant examination may also be different from an adult who has been assessed and found not to have the feature. In a family history, record age, what was examined and whether a diagnosis was confirmed.
For some conditions, different manifestations have different penetrance. A biochemical finding, a scan abnormality and symptoms affecting everyday life should not be treated as interchangeable endpoints. Our HFE hemochromatosis guide illustrates why a genetic predisposition, abnormal iron studies and organ damage are distinct findings.
Why members of one family can differ
Other genetic factors, age and environmental influences can contribute to variation. Sometimes the reasons remain uncertain. The NHS genomics communication aid provides a useful way to discuss this without implying that a shared variant produces identical outcomes.
A family’s experience is valuable clinical evidence, but a small family is not a precise risk calculator. A strikingly severe case can dominate everyone’s expectations; a mildly affected relative can create false reassurance. Both deserve attention, alongside evidence from appropriately studied groups.
Reduced penetrance is different from a VUS
A variant of uncertain significance means that its relationship to disease is unresolved. Reduced penetrance can apply to a variant already established to increase disease risk. Uncertainty about causation and uncertainty about individual outcome are different.
Fictional teaching example. Two reports each leave a patient unsure about the future. One identifies a well-established predisposition variant whose effects vary between people. The other identifies a VUS. The first discussion concerns the known condition’s risk and appropriate follow-up; the second must avoid treating the uncertain variant as an established explanation. The same reassuring phrase, “It may never affect you,” would obscure that difference.
A checklist for reading a penetrance estimate
- Identify the exact variant or group of variants studied.
- Check which feature counts as an outcome.
- Look for age-specific estimates and the length of observation.
- Ask how participants were recruited: a specialist clinic may include more severe cases than a population sample.
- Check whether apparently unaffected people had relevant assessments.
- Read uncertainty intervals and sample size, rather than quoting one percentage as universal.
The NHS definition of penetrance is a starting point. Translating a published estimate into personal care requires a clinician who can assess whether that evidence fits the person and family.
Questions to take to a genetics appointment
- Which outcome are we discussing, and over what age range?
- Does this number come from families like mine or from a different study population?
- Which findings can vary, even among relatives?
- What monitoring is supported by the evidence?
- What new family information would change the interpretation?
Use the variant-research worksheet to organize the report and sources, or the genetics-care directory to locate appropriate services. For the separate question of transmission, see MedlinePlus inheritance probabilities.